Ovarian Cancer State of the Art and New Developments

by Jacobs, Ian; Shepherd, John; Oram, David; Blackett, Tony; Luelsey, David; Berchuck, Andy; Hudson, Chris

• ISBN13: 9780198508267
• ISBN10: 0198508263
• Edition: 2nd
• Format: Hardcover
• Copyright: 2002-05-02
• Publisher: Oxford University Press

Summary

Ovarian cancer provides an up-to-date and comprehensive synthesis of clinical management and research progress in the field of epithelial ovarian cancer. The book has its origins in two separate but complementary initiatives. One initiative was a series of reviews commissioned to cover thespectrum of clinical management of ovarian cancer from prevention, screening and diagnosis to surgery, chemotherapy and palliative care. The reviews were invited from an international panel of clinicians with expertise in the management of ovarian cancer. The second initiative was co-ordinated bythe Helene Harris Memorial Trust (HHMT) which has organised key biennial meetings on ovarian cancer for the last 12 years. Attendance at the meetings is by invitation to a small group of international authorities on research aspects of ovarian cancer. Setting the clinically focused reviewsalongside the HHMT research focused chapters has created a unique book. First, the book is unusually up-to-date and presents recent advances not included in other books in this field. Second, the contents are comprehensive and cover aetiology, pathology, screening, prevention, diagnosis,prognostic techniques, surgery, adjuvant therapy and palliative care. Third, the review chapters are set alongside more detailed coverage of recent clinical and basis science developments. Examples of this are the coverage of familial cancer, prevention, screening, and current therapy which areconsequently much more topical and exciting. Fourth, there are sections on 'tumour biology' and 'novel therapies' which have not been covered in comparable books about ovarian cancer. Finally, the contributions are from a representative spectrum of experts from both research and clinicalbackgrounds and with a truly international perspective.

Author Biography

Editorial Chairs: Professor CN Hudson Editor of the First Edition, extremely high profile internationally, Professor of Obstetrics & Gynaecology, St Bartholomew's Hospital, London. Professor Ian Jacobs Original Editor and also a member of the Helene Harris Memorial Trust. In 1996 he was appointed to his current post which involves both clinical responsibilities for gynaecological oncology and direction of the Gynaecological Cancer Research Unit at St Bartholomew's and The Royal London Hospitals Medical School. In addition to directing the molecular and clinical studies organised through this unit, Ian Jacobs is co-ordinator of national collaborative studies of interval debulking surgery in ovarian cancer (MRC) and of screening for familial ovarian cancer (UKCCCR). Editorial Board Dr John Shepherd Editor of the First Edition, extremely high profile internationally, based at St Bartholomew's Hospital, London.where he has established the largest (and arguably the most prestigious) g

Table of Contents

List of contributors	xiii
Abbreviations	xxi
Part 1 Aetiology
Epidemiology of sporadic ovarian cancer	3	(6)
Daniel W. Cramer
Associations between infertility, its treatment, and ovarian cancer risk	9	(6)
Ingemar Persson
The molecular basis of sporadic ovarian cancer	15	(14)
Angeles Alvarez
Andrew Berchuck
Overview of the aetiology of familial ovarian cancer	29	(8)
Ronald P. Zweemer
The prevalence of mutations in BRCA1 and BRCA2	37	(4)
Michael R. Stratton
The penetrance of BRCA1/2 mutations	41	(4)
Jeffery P. Struewing
Founder mutations of BRCA1/2	45	(4)
Uziel Beller
Baruch Modan
Ofer Lavie
Bella Kaufman
Galit Hirsh-Yechzkel
Orit Gotfeld
Angela Chetrit
Raphael Catane
Ephrat Levy-Lahad
Clinical implications of genetic testing	49	(8)
Andrew Berchuck
P. Andrew Futreal
Joellen S. Schildkraut
Part 2 Natural history and Pathology
Pathology of epithelial ovarian cancer	57	(10)
Harold Fox
Naveena Singh
Pathology of borderline ovarian malignancy	67	(8)
Harold Fox
Primary non-epithelial ovarian cancers	75	(10)
Naveena Singh
David Lowe
Metastases in the ovary	85	(6)
Naveena Singh
David Lowe
Genetic analysis of putative precursors of ovarian cancer	91	(6)
Ian G. Campbell
Sarah J. Morland
Koshiro Obata
Phillippa J. Neville
Nicola Thomas
Molecular pathogenesis of borderline and invasive ovarian tumours	97	(10)
Samuel C. Mok
Karen H. Lu
Shu-wing Ng
Gary K. Tiu
William R. Welch
Debra A. Bell
Ross S. Berkowitz
Part 3 Tumour biology
The application of novel technology to the study of ovarian cancer	107	(6)
Monica R. Brown
Michael Emmert-Buck
David B. Krizman
Emmanuel Petricoin
Lance A. Liotta
Elise C. Kohn
The biology of the ovarian surface epithelium	113	(6)
Rudi Bao
Abbas Abdollahi
Thomas C. Hamilton
The tumour microenvironment of epithelial ovarian cancer	119	(6)
Frances Burke
Chris Scotton
Kate Scott
Robert Moore
Caroline Arnott
Fran Balkwill
ARH1 (NOEY2), a novel imprinted tumor suppressor gene in ovarian cancer	125	(6)
Yinhua Yu
Fengji Xu
Hongqi Peng
Xianjun Fang
Shulei Zhao
Weiya Xia
Wen-lin Kuo
Joe W. Gray
Michael Siciliano
David Hogg
Andrew Berchuck
Kelly Hunt
Gordon B. Mills
Robert C. Bast, Jr
Regulation of angiogenesis in ovarian cancer: role of p53, vascular endothelial growth factor, and hypoxia	131	(6)
E. Ferreux
C.E. Lewis
C.W. Perrett
M. Wells
Role of Fas/FasL in the control of human ovary cancer growth and progression	137	(8)
Delia Mezzanzanica
Alessandra Mazzoni
Donatella R.M. Negri
Mariangela Figini
Maria I. Colnaghi
Silvana Canevari
Part 4 Prevention and screening
The surgical prevention of ovarian cancer	145	(8)
David H. Oram
Chemoprevention of ovarian cancer	153	(8)
Christine E. Szarka
Thomas C. Hamilton
Andres J.P. Klein-Szanto
Robert F. Ozols
Biologic effect of progestins on ovarian epitheium: cancer prevention through apoptosis?	161	(10)
Gustavo C. Rodriguez
David Walmer
Mark Cline
Hannah Krigman
Regina Whitaker
Pamela D. Isner
Bruce Lessey
Connette McMahon
Jeffrey Marks
James Petitte
Donna Carver
Kenneth Anderson
Andrew Berchuck
John Barnes
Claude Hughes
The current status of screening for ovarian cancer	171	(8)
Usha Menon
Ian J. Jacobs
Optimizing the use of ultrasonography in ovarian cancer screening	179	(4)
Paul DePriest
Doppler ultrasound derived indices in screening and diagnosis of ovarian cancer	183	(6)
Kenneth J.W. Taylor
Andrea Lundell
Differentiating the risk of ovarian cancer calculation from CA125 velocity: a new concept for optimizing CA 125 screening for ovarian cancer	189	(10)
Steven J. Skates
Socio-economics of ovarian cancer screening	199	(10)
Nicole Urban
Martin McIntosh
Lauren Clarke
Ian Jacobs
Beth Karlan
Garnet Anderson
Charles Drescher
The management of familial ovarian cancer	209	(12)
Paul D. Pharoah
James Mackay
Part 5 Diagnostic and prognostic techniques
Clinical diagnosis including paraneoplastic syndromes	221	(12)
Chris N. Hudson
Thomas J. Ind
O. Marigold Curling
Serum tumour markers in the clinical management of ovarian cancer	233	(10)
Robert P. Woolas
Three-dimensional ultrasound and color-flow studies	243	(14)
A. Kurjak
S. Kupesic
CT and MRI of ovarian cancer	257	(12)
S.A.A. Sohaib
R.H. Reznek
Radionuclide imaging	269	(6)
Keith E. Britton
Faria Nasreen
Hikmat Jan
Marie Granowska
Telomerase in ovarian cancer: a possible diagnostic tool and therapeutic target?	275	(6)
G. Bea A. Wisman
Marco N. Helder
Steven de Jong
Elisabeth G.E. de Vries
Ate G.J. van der Zee
Detection of circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian cancer	281	(8)
Christian Marth
Hanne Høifødt
Lise Walberg
Janne Kæarn
Ole Mathiesen
Marianne Andresen
Claes Trope
Øystein Fodstad
Part 6 Surgical treatment and organization of care
Overview of primary surgery for ovarian cancer	289	(10)
Thomas E.J. Ind
John H. Shepherd
Interval debulking surgery significantly increases the survival and progression-free survival in advanced epithelial ovarian cancer patients: an EORTC Gynaecological Cancer Co-operative Group study	299	(6)
Maria E.G. van der Burg
Mat van Lent
Anna Kobierska
M.R. Pittelli
Guiceppe Favalli
Angel J. Lacave
M. Nardi
Guido Hoctin Boes
Ivana Teodorovic
Sergio Pecorelli
The role of surgery in relapse and palliation of ovarian cancer	305	(6)
Sean Kehoe
Christopher Mann
The role of minimal access surgery in ovarian cancer	311	(8)
Robin A.F. Crawford
The organization of care	319	(4)
H.C. Kitchener
Patterns of care in ovarian cancer	323	(10)
Edward L. Trimble
Part 7 Adjuvant and palliative therapy for ovarian cancer
Current chemotherapy options in ovarian cancer	333	(8)
Martin Gore
Francisco Sapunar
David Gibbs
Chemotherapy for epithelial cancer of the ovary	341	(10)
Jonathan Shamash
Maurice Slevin
Neoadjuvant chemotherapy in advanced ovarian carcinoma: present and future prospects	351	(4)
Ignace Vergote
Randomized trials in epithelial ovarian cancer: the Gynecologic Oncology Group studies	355	(8)
Jonathan S. Berek
Robert F. Ozols
Part 8 Novel therapies: the future
Angiogenesis in epithelial ovarian cancer: an important biologic event and therapeutic target	363	(8)
Elise C. Kohn
Delivery of genes to ovarian cancer using targeted vectors based on self-assembling polymers	371	(6)
Kerry D. Fisher
Christopher M. Ward
Nigel Acheson
Leonard W. Seymour
Corporate drug discovery strategies	377	(2)
Mark P. Smith
George R. P. Blackledge
DNA mismatch repair and drug resistance	379	(6)
Stephen B. Howell
Xinjian Lin
Heung-Ki Kim
Gene therapy and immunomodulation	385	(6)
Rosalind Graham
Michael Smith
Lukas Heukamp
Izsabel Correa
Tim Plunkett
Moira Shearer
David Miles
Joy Burchell
Joyce Taylor-Papadimitriou
Preclinical and phase I clinical studies of combinations of chemotherapy with recombinant adenovirus containing full-length, human p53 tumor suppressor gene cDNA for p53-mutant ovarian cancer	391	(8)
M.D. Pegram
G. Konecny
R. Buller
I. Runnebaum
D.J. Slamon
L.L. Nielsen
J. Horowitz
B.Y. Karlan
Paclitaxel resistance in human ovarian cancer: role of apoptosis-related proteins	399	(8)
Stephen R.D. Johnston
Mansour S. Al-Moundhri
Lloyd R. Kelland
Martin E. Gore
Trials of p53 gene therapy: rationale and Preliminary studies	407	(6)
R.E. Bulter
M. Pegram
I. Runnebaum
JoAnn Horowitz
T.E. Buekers
Thomas P. Salko
M.E. Rybak
M.S. Shahin
R. Kreienberg
B. Karlan
D. Slamon
Phosphatidylinositol 3'-kinase as a target in ovarian cancer: from genomics to therapeutics	413	(10)
Yiling Lu
Laleh Shayestri
Ruth Lapushin
Singxing Yu
Bruce Cuevas
Xianjun Fang
Astrid Eder
Tatsuro Furui
Daniel Plikoff
Wen-Lin Kuo
Russ Baldocchi
Bart Vanhaesebroeck
Robert C. Bast
Dan Pinkel
Kathy Siminovitch
Robert Jaffe
Joe Gray
Gordon B. Mills
Index	423